

PHARMACEUTICAL 2023











RealRate

PHARMACEUTICAL 2023



Acasti Pharma Inc. Rank 59 of 446

The relative strengths and weaknesses of Acasti Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acasti Pharma Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 117% points. The greatest weakness of Acasti Pharma Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 237%, being 194% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	45,531
Cost of Goods Sold	0
Intangible Assets	82,774
Liabilities, Current	3,260
Liabilities, Non-Current	191
Other Assets	315
Other Compr. Net Income	0
Other Expenses	119
Other Liabilities	16,899
Other Net Income	5,122
Other Revenues	0
Property and Equipment	0
Research and Development	5,559
Selling, General and Administrative Expense	9,263

Output Variable	Value in 1000 USD
Assets	128,620
Liabilities	20,350
Expenses	14,941
Revenues	0
Stockholders Equity	108,270
Net Income	-9,819
Comprehensive Net Income	-9,819
Economic Capital Ratio	237%

